Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.
|Videos|September 18, 2020
Prolapse surgery outcomes compared in nursing home residents, community-dwelling adults
Author(s)Urology Times staff
Anne M. Suskind, MD, MS, discusses the findings of the recent study, published in Urology.
Advertisement
In this interview, Anne M. Suskind, MD, MS, discusses a recent Journal of Urology study in which she and her co-authors compared outcomes for pelvic organ prolapse surgery in nursing home residents and community-dwelling older adults. Suskind is associate professor of urology at the University of California San Francisco.
Advertisement
Related to this article
Chad Ritch, MD, discusses how PSMA-PET informs patient management across different stages of the prostate cancer journey.
Alicia K. Morgans, MD, MPH, reviews promising prostate cancer findings from ESMO 2026,
Alberto Briganti, MD, PhD, discusses results from the PROTEUS substudy, evaluating perioperative apalutamide plus ADT vs surgery alone in high-risk localized or locally advanced prostate cancer.
Andrea Necchi, MD, discusses how results from the CA017-078 trials compares with other perioperative immunotherapy trials in muscle-invasive bladder cancer.
Daniel Heng, MD, discusses final LITESPARK-011 results, including sustained PFS benefit with belzutifan plus lenvatinib vs cabozantinib in advanced ccRCC.
Carlos A. Vargas, MD, discusses updated survival outcomes, safety, and the mechanism of SYNC-T SV-102, an investigational in situ immunotherapy for metastatic prostate cancer.
Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.
Advertisement
Advertisement
Trending on Urology Times
1
Factors shaping PSMA-PET agent selection in prostate cancer
2
Nogapendekin alfa inbakicept plus BCG advances to final analysis in BCG-naïve NMIBC
3
Chad Ritch, MD, on using PSMA-PET to guide treatment decisions
4
Alicia Morgans, MD, MPH, highlights key prostate cancer data from ESMO 2026
5